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文
Abstract 
Plasma cel myeloma (PCM) is a d巴vastatingdisease with a highly heterogeneous outcome, 
with survival ranging企oma few months to longer than 10 years. Treatment of multiple 
myeloma has changed markedly in the past decad巴dueto the developm巴ntof new drugs such 
as bortezomib, lenalidomide and thalidomide, wl吐chhave greatly improved the outcome of 
PCM. The clinical and prognostic value of immunophenotyping in PCM remains 
questionable. The aim of this study was to determine the diagnostic and prognostic 
significance of CD200 expr巴ssionin newly diagnosed PCM. We retrospectively reviewed the 
records of 107 patients newly diagnosed with PCM at Showa University Hospital between 
Januぽy2004 and S巴ptember2013. Expression of CD200 was studied by 
immunohistochemistry. Clinical and pathological p紅白netersw巴recomp紅edbetween 
CD200”・positive and CD200-negative cases. CD200・positivePCM cases had lower serum 
albumin (p =0.0001) compared to those without CD200 expression. Our results showed no 
significant differenc巴inmedian ov巴railsurvival between patients with CD200-positiv巴and
CD200”negative PCM. However，吐ierewas a strong correlation between CD200 expression 
and serum albumin level. In the CD200-n巴gativegroup, median overall survival was 
significantly long巴rin patients who r巴ceivednew drug treatment. These findings suggest that 
CD200 expression is a useful mark巴rfor evaluation of the severity of PCM and that lack of 
CD200 expression may improve th巴sensitivityof PCM to therapy with n巴w批ugs.
K巴ywords:CD200, Plasma c巴1myeloma, Immunohistochemistry, Albumin, new drugs 
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Introduction 
Plasma cel myeloma (PCM) is a devastating disease with a highly heterogeneous outcome. 
Treatment of multiple my巴Jomahas changed in白巴pastd巴cad巴dueto development of drugs 
such as bo此ezomib,lenalidomide and thalidomide, 14 and the prognosis of PCM has been 
greatly improved by these drugs. Stil, survival rang巴S企omaf巴wmonths to longer than I 0 
years, and several staging methods using clinical and laboratory p紅amet巴＇rshave be巴n
proposed to identifシpatientswith poor prognos巴s.Among these, the Durie-Salmon staging 
system (DSS), which includes the I巴velsand types of monoclonal proteins, hemoglobin 
concen甘ation,serum calcium level, number of bone lesions, and creatinine level, has b巴巴n
widely adopt巴das a star ar’d staging system.5 Serum beta-2 microglobulin (S~2M) 
measurement has巴mergedas the single most powerful predictor of survival in several 
subsequent studies. The serum albumin level has also be巴nrecog凶zedas a significant 
prognostic factor that improves th巴prognosticsignificance of SP2M measureme凶.In 2005, 
由巳InternationalStaging System (ISS) was introduced as a three-stage classification using 
Sp2M如 dserum albumin levels as a simple, powerful and reproducible system. 6 
M ulti-paramet巴r丑owcytometry imrnunophenotyping is increasingly used for diagnostic 
and prognostic evaluation of hematologic malignancies including PCM, 7 using diagnostic 
markers such as CD56. However, the clinical and prognostic value of immunophenotyping in 
PCM remains questionabl巴.s,9 R巴cently,expression of CD200 has been associated with a 
poor prognosis in PCM patien臼.10CD200, which was initially d巴scribedas白eOX-2知mor
antigen, is a transmembrane glycoprot巴inthat is a potential therapeutic target due to its role in 
immune regulation and toleranc巴.CD200 is expressed on the cel surfac巴ofthymocytes,B 
and T lymphocytes, ne町ons,kidn巴yglomeruli, tonsil follicles, syncytiotrophoblasts and 
endothelial cels, 1 and in melanoma, renal cel carcinoma, and ovarian tumor cels. CD200 
is also expressed in hematological malignancies such as acute leukemia, chronic l戸nphocytic
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l巴ukemia/smalllymphocytic lymphoma, hairy cell leukemia, classical Hodgkin lymphoma, 
and angioimmunoblastic T-cell lymphoma. 12-14 It has recently been hypothesized that CD200 
may play an important role in t山norprogression because of its immunosuppressive effect on 
th巴hostimmune system. 15 
Normal plasma cells have no or weak CD200 expression in assessment by flow 
cytome仕y,16 whereas most PCM cells express CD200 strongly. Immunophenotypic analysis 
is mainly used for detection of PCM cells in atypical cases of PCM. There is a paucity of 
literature on CD200 in PCM，組dthe effe向。fCD200 expression悶 unclear.Thus, 
CD200-negative PCM has been suggested to have better event-fr・eesurvival (EFS) compared 
with CD200中ositivePCM;10 but loss ofCD200 expression in PCM has also been associated 
with a more clinically aggressive disease. 17 Differences in findings may aris巴dueto analysis 
of PCM cells after anti-myeloma therapy or at initial diagnosis of PCM. Regardless, it is clear 
that PCM may be a us巴おlprognostic indicator. Therefor巴，theaim of this study was to 
analyze expression of CD200 in newly diagnos巴dPCM and to define the relationships 
between CD200 expression and other clinical and pathological par出国ters.
Materials and Methods 
The subjects were 107 patients (64 males and 43 females) of median age 69 years (range, 
39-92 years). All cases were newly diagnosed with PCM at Showa University Hospital 
between J anu紅y2004 and September 2013. Medical records were revi巴wedto obtain clinical 
information, including therapy regimens, laboratory data, and overall survival (OS). 
Morphologic切 dimmunophenotypic data w悶 r巴viewedto confirm the diagnosis according 
to 2008 WHO criteria. 
Morphological findings were obtained using H&E stains of 3-μm sections. Formalin-fixed, 
P訂affin-embeddedspecimens were used for IHC with the following antibodies: CD200 
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(polyclonal, goat; R&D Systems, Minneapolis, MN, USA), CD138 (clon巴MI15;Dako 
Cytomation A/S, Glostrup, Denmark), CD56 (clone 1B6; Novocastra, Newcastle, UK). 
CD200 and CD56 immunostained slides wer巴definedas positive if>30%。fplasmac巴!lshad 
moderate to strong membranous staining. Statistical analysis was p巴rfoロnedusing JMP 11 
(SAS Institut巴Inc.,Cary, NC, USA). A x2test was used to compare clinical and pathological 
features between白eCD200-positive and CD200・negativegroups. A Wilcoxon signed-r紅lk
test was us巴dto comp紅elaboratory data between these groups. OS was analyzed using the 
Kaplan・Meiermethod and compared by gen巴ralizedWilcoxon test. A p value< 0.05 was 
considered significant in al analys巴s.
Results 
The study cohort included 64 men and 43 women, wi廿la median age of 69 ye釘S(range, 
39-92 ye間）.The immunoglobulin heavy chain type was IgG in 53 patients, IgA in 29, IgD 
in 1, and BJP in 30. One patient had non-secretory PCM. In the Durie-Salmon classification, 
68 (64%) of patients wer巴inStage II. In the ISS, 19 (18%), 32 (30%), and 47 (44%) of 
patients were in stag巴SI, I, and II, respectively. 6 Among血e90 patients who received any 
therapy, 52 were treated with new drugs (bortezomib (n=44), lenalidomide (n=24) or 
thalidomid巴（n=6))during the course of the dis回se,and 3 8 received conv巴ntionalhigh dose 
chemotherapy only. Median S~2M was 4.9 g/dL, creatinine 0.97 mg/dL, calcium 9.3 mg/dL, 
albumin 3.3 g/dL, lactat巴dehydrogenas巴（LDH)180.5 IU/L, and hemoglobin (Hb) 9.9 g/dL. 
Bas巴linecharacteristics are shown in Table 1. 
Of th巴107cas巴s,71 (66.3%) had CD200 expression in PCM cells (Figure 1). The 
clinical and pathological features of th巴CD200・positiveand CD200-negative groups w紅白
similar for age, gender, light chain restriction, S~2M level, LDH, and Hb (Table 2). However, 
significantly more patients in the CD200・positivegroup had a low巴rserum albumin （三3.5
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mg/dL) (71.8% vs. 38.9%, p<0.0001). There was no significant correlation b巴tweenCD200 
expression and SP2M. Similar trends w悶 see山 comparisonsamong ISS stages. In the 
CD200・positivegroup, the m閃且serumalbumin level was significantly lower (p=0.0003) and 
th巴rateofCD56 expression was significantly higher (p<0.001) compared to the 
CD200-negative group (p<0.001). Median OS in the CD200・positivegroup showed a 
tendency to be longer than that in the CD200-n巴gativegroup, but the difference was not 
significant (p=0.31) (Figure 2A). The s巴rumalbumin level also had no significant effect on 
me di釦 OS(p=0.87) (Figure 2B). 
In a subgroup analysis based on therapy regimens, in the CD200-negative group the 
median OS of patients who received new drug therapy was significantly longer than that of 
patients who received only conventional high dose th巴rapy.This effect was not present in th巴
CD200-positive group (Figure 3). For CD56 expression, th巴rewas no significant difference 
in median OS in subgroup analysis based on the therapy regimen. 
Discussion 
PCM isan incurable neoplastic plasma cel disorder characterized by proliferation of 
clonal malignant plasma cells in bone m紅row.Survival rates in patients with PCM are 
variable, reflecting the heterogeneity of PCM cel biology. CD200 may be a useful prognostic 
marker in PCM because of its immunosuppr巴ssiveeffect on the host immune system.10・ 18 
Lower serum albumin is currently viewed as仕1巴mostuse釦lm町kerof a poor prognosis in 
6 19,20 PCM. 
In社usstudy, CD200 expression was exanlined in 107 cases of PCM using IHC. CD200 
was expressed on PCM cells in 71 %。fcases, similarly to previous findings. 18 Lower SP2M 
has b巴enfound in CD200-positive cases (p=0.03),21 but O町 resultsshowed no co立elationof 
CD200 expression with low SP2M levels. In contrast, lower serum albumin levels were 
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significantly more common in CD200-pos江ivecases than in CD200-negative cases 
(p=0.0001). The SP2M level is a powerful predictor of survival in PCM. However it should 
be noted that the serum albumin level improves the prognostic significance of SP2M, as used 
in the ISS. The specific caus巴ofdecreased serum albumin in PCM patients with a poor 
prognosis is uncertain. 6 The balanc巴amongproduction by the liver and d巴gradation
determines the concentration of serum albumin, and effects on the !iv巴rof interleukin-6 
produced by出emicroenvironment of PCM cels may decrease albumin production目19,2, 23 
Renal failure or nephrotic syndrome induced by PCM may also decrease th巴levelof albumin. 
However, there was no significant differenc巴inkidn巴yfunction decline between the CD200 
-positive and -negative groups in this study, based on白elevels of serum creatinine and 
SP2M. 
CD200 expression was not associated with survival in our cohort, whereas a previous 
report found that CD200 expression is associated with worse EFS.10・ 18 However, this is 
uncertain, because a flow cytometry study suggested that CD200・positivePCM had a better 
outcome than CD200-negative cases. 17 The CD200-CD200R interaction is a pot巴ntialtarget 
for immunomodulation and CD200 delivers an inhibitory signal for the macrophage lineage 
in div巴rsetisues. 24 In addition to being expressed in normal tissues, CD200 isぬnctionally
involved in an immunosuppr巴ssivesignaling pathway via interaction with its receptor, 
CD200R, with downstream effects on macrophage inhibition, induction of regulatory T cels, 
and inhibition of tumor-specific T cels. Molecular signaling pathways activated in the tumor 
environment help to create an immunosuppressive network, through which the cancer 
escapes detection. This could explain the worse EFS of CD200圃positivePCM found in som巴
studies. 
In our study, no results seemed to depend on吐ieCD200-CD200R interaction, and there 
was no difference in OS between the CD200・positive組 d-negative groups. This suggests 
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that the function of CD200 and its regulation in PCM iscomplex, and a further study is 
required. As reported previously, CD200 was expressed in most cases of PCM and there was 
a strong correlation between expression of CD200 and CD56. CD56 is a m巴mbrane
glycoprot巴inand adhesion molecule that belongs to the immunoglobulin superfamily. CD56 
expression correlates with the ability of c巴lsto migrate out of bone marrow, and modulation 
ofCD56巴xpr巴ssionis a potential mechanism of regulation of plasma cel homing to 
extramedullary sites. 25 Currently, CD56 is used as a diagnostic marker for PCM cels, 
although there is no cons巴nsuson CD56 as a prognostic marker in PCM. CD56 may be more 
use白lthan CD200 as a diagnostic mark巴rbecause it is typically negative in normal plasma 
cels, while CD200 is weakly positive. 9 However, CD200 expression in PCM may be useful 
in follow up analysis due to its stability.17•26 Furthermore, our results suggest that CD200 
expression may be a good indicator for the choice of therapy. 
In summary, we found that expression of CD200 is a reliable marker for PCM diagnosis. 
The s廿ongco町elationof CD200 expression with a low serum albumin level suggests that 
CD200 could also be a useful marker for evaluation of the severity of PCM. With reg紅dto 
prognosis, patients who訂eCD200-negative may be more responsive to tr官atm巴ntwith drugs 
such as bortezomib, lenalidomide and thalidomide. Thus, CD200 immunohistochemistry may 
be a useful indicator for the choice of PCM treatment. A further study in a larger number of 
cases is needed to confirm th巴sefindings. 
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Figure Legends 
Figure 1. CD200 expression in plasma cell myeloma. A: Representative cas巴withstable 
CD200 expr回sion:（吟H&E,(b) CD138 and (c) CD200 immunostains. B: Representative 
cas巴witha lack ofCD200 expression: (d) H&E, (e) CD138 and （今CD200immunostains. 
Figure 2. A. Overall survival (OS) in CD200-positiv巴（n=71)and CD200-negative (n=36) 
patients with PCM. B. OS in patients with PCM with higher （と3.5g/dl, n=42) and lower 
(<3.5 g/dl, n=65) lev巴lsof serum albumin. 
Figure 3. A. Overall survival (OS) in CD200”・positive patients who received new drug 
therapy (n=33) or conventional high dose therapy only (n=27). B. OS in CD200-n巴gative
patients who received new drug therapy (n=19) or conventional high dos巴therapyonly 
(n=ll). 
Table 1. Baseline clinical and laboratory features in patients with PCM 
Table 2. Comparison of clinical and pathological features in the CD200-positive佃 d
CD200-negative groups 
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Tab！巴2
Comparison of clinical features in th巴CD200-positiveand 
CD200-negative groups 
CD200(+) CD200（”） p-value 
n 71 36 
Age>65ye紅s(%) 71.8 66.7 0.650 
Male(%) 60.6 58.3 0.830 
Kappa(%) 57.8 41.7 0.150 
Lambda(%) 38.0 52.8 0.146 
IgG(%) 54.9 38.9 0.110 
IgA(%) 28.2 25.0 0.726 
SP2M<3.5mg/dL(%) 11.3 22.2 0.377 
SP2M>5.5mg/dL(%) 11.3 47.2 0.507 
Alb<3.5g/dL(%) 71.8 38.9 0.001 * 
Hb<!Og/dL(%) 49.3 52.8 0.848 
Creatinine> l .5mg/dL(%) 25.5 20.0 0.780 
Calcium> I 0.5mg/dL(%) 11.3 22.2 0.157 
CD56(+)(%) 81.7 52.8 0.003* 
SP2M, beta-2 microgrobulin; Alb, albumin; Hb, hemoglobin; 
*p<0.05 
Table I 
Baseline clinical and laboratory fe鉱山巴sin patients with PCM 
n= 107 No. of cases(%) 
Sex 
Male 64(59) 
Female 43(40) 
Age 
Median 69 years 
Range 39-92 years 
Durie-Salmon stage 
I 17(16) 
I 21(19) 
II 68(63.5) 
unknown !(!) 
International staging system 
19(18) 
I 32(30) 
II 47(44) 
山水nown 9(8) 
Immunoglobulin heavy chain type 
IgG 53(50) 
IgA 29(27) 
IgD !(!) 
BJP 30(28) 
Non secretory !(!) 
Treated with new drugs 52(49) 
Bortezomib 44(41) 
Lenalidomide 24(22) 
Thalidomide 6(6) 
No treatment with new drugs 38(36) 
Sp2M,mg/L 4.9土6.3
Creatinine, mg/ di 0.97土2.94
Calcium, mg/di 9.3土1.31
Albumin, mg/di 3.3土0.65
LDH, IU/L 180.5土185.6
Hb, g/dl 9.9土2.61
Sp2M, beta-2 microgrobulin; LDH,lactate dehydrogenase; Hb, hemoglobin 
Data紅eshown as median土SD
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A. Overall survival (OS) in CD200-positive patients 
who received new drug therapy (n=33) or conventional high dose therapy only (n=27). 
B. OS in CD200-negative patients who received new drug therapy (n=19) 
or conventional high dose therapy only (n=ll). 
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Figure 2. 
A. Overall survival (OS) in CD200四positive(n=71) and CD200-negative (n=36) patients with PCM. 
B. OS in patients with PCM with higher (2':3.5 g/dl, n=42) and lower (<3.5 g/dl, n=65) levels of serum albumin. 
